NIKKEI 225
26,469.48 -102.39 (-0.39%) HANG SENG
17,860.31 +5.17 (+0.03%) CRUDE OIL
78.70 +0.20 (+0.25%) GOLD FUTURES
1,637.20 +1.00 (+0.06%) DOW
29,134.99 -125.82 (-0.43%) BTC-GBP
17,899.93 -178.18 (-0.99%)
Apontis Pharma AG (APPH.F)
| Previous close | 7.58 |
| Open | 7.18 |
| Bid | 6.92 x N/A |
| Ask | 7.88 x N/A |
| Day's range | 7.18 - 7.18 |
| 52-week range | 7.18 - 27.30 |
| Volume | |
| Avg. volume | 206 |
| Market cap | 61.03M |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.17 |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 29.00 |
- EQS Group
APONTIS PHARMA announces cooperation to launch new Single Pill in Germany
EQS-News: APONTIS PHARMA AG / Key word(s): Alliance/Product LaunchAPONTIS PHARMA announces cooperation to launch new Single Pill in Germany 20.09.2022 / 07:30 CET/CESTThe issuer is solely responsible for the content of this announcement.APONTIS PHARMA announces cooperation to launch new Single Pill in Germany Single Pill for more efficient treatment of hypertension with potential peak sales of more than EUR 15.0 million Potential patient population of more than a million people Market launch pla
- EQS Group
APONTIS PHARMA: SECURE study and START study add-on analysis confirm superior efficacy of Single Pill
DGAP-News: APONTIS PHARMA AG / Key word(s): Scientific publicationAPONTIS PHARMA: SECURE study and START study add-on analysis confirm superior efficacy of Single Pill 01.09.2022 / 07:30 CET/CESTThe issuer is solely responsible for the content of this announcement.APONTIS PHARMA: SECURE study and START study add-on analysis confirm superior efficacy of Single Pill SECURE study and START study add-on analysis results presented at European Society of Cardiology Congress (ESC) in Barcelona Single P
- EQS Group
APONTIS PHARMA expands profitable positioning in first half of 2022 – full-year forecast confirmed
DGAP-News: APONTIS PHARMA AG / Key word(s): Half Year Report/Half Year ResultsAPONTIS PHARMA expands profitable positioning in first half of 2022 – full-year forecast confirmed 11.08.2022 / 07:30 The issuer is solely responsible for the content of this announcement.APONTIS PHARMA expands profitable positioning in first half of 2022 – full-year forecast confirmed Revenue from Single Pills +26.0% to EUR 17.7 million remains a key growth driver Single Pill share of revenue increases to 62.9% (H1 20
